Evidence map›Paper›PMID 30627566›Full record

Trial reportBioMed research international2018

Mass Spectrometry-Based Comprehensive Analysis of Pancreatic Cyst Fluids.

Agnieszka Paziewska, Marcin Polkowski, Tymon Rubel, Jakub Karczmarski, Anna Wiechowska-Kozlowska, Michalina Dabrowska, Michal Mikula, Michal Dadlez, Jerzy Ostrowski

Open access · hybridAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Advances in the Diagnosis of Pancreatic Cystic Lesions.Diagnostics (Basel, Switzerland) · 2022
    Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Agnieszka PaziewskaDepartment of Gastroenterology, Hepatology and Clinical Oncology, Medical Center for Postgraduate Education, Warsaw, Poland.
Marcin PolkowskiDepartment of Gastroenterology, Hepatology and Clinical Oncology, Medical Center for Postgraduate Education, Warsaw, Poland.
Tymon RubelInstitute of Radioelectronics and Multimedia Technology, Warsaw University of Technology, Warsaw, Poland.
Jakub KarczmarskiDepartment of Genetics, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Anna Wiechowska-KozlowskaDepartment of Endoscopy, Ministry of Internal Affairs Hospital, Szczecin, Poland.
Michalina DabrowskaDepartment of Genetics, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Michal MikulaDepartment of Genetics, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.ORCID 0000-0003-3447-7328
Michal DadlezInstitute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland.
Jerzy OstrowskiDepartment of Gastroenterology, Hepatology and Clinical Oncology, Medical Center for Postgraduate Education, Warsaw, Poland.ORCID 0000-0002-1450-8564
Postgraduate School of Molecular Medicine · PLThe Maria Sklodowska-Curie National Research Institute of Oncology · PLInstitute of Biochemistry and Biophysics, Polish Academy of Sciences · PLUniversity of Szczecin · PLWarsaw University of Technology · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cyst fluids (PCFs) enriched in tumour-derived proteins are considered a potential source of new biomarkers. This study aimed to determine compositional and quantitative differences between the degradome and proteome of PCFs aspirated from different types of pancreatic cyst lesions (PCLs). 91 patients who underwent endoscopic ultrasound-fine needle aspiration under routine clinical diagnosis of PCLs were enrolled. Four cysts were malignant (CAs), and 87 were nonmalignant and consisted of 18 intraductal papillary mucinous neoplasms (IPMNs), 14 mucinous cystic neoplasms (MCNs), nine serous cystic neoplasms (SCNs), 29 pseudocysts (PCs), and 17 unclassified. Profiles of the <5 kDa fraction, the degradome, and the trypsin-digested proteome were analysed using an LTQ-Orbitrap Elite mass spectrometer coupled with a nanoACQUITY LC system. Qualitative analyses identified 796 and 366 proteins in degradome and proteome, respectively, and 689 (77%) and 285 (78%) of them were present in the Plasma Proteome Database. Gene Ontology analysis showed a significant overrepresentation of peptidases and peptidases inhibitors in both datasets. In the degradome fraction, quantitative values were obtained for 6996 peptides originating from 657 proteins. Of these, 2287 peptides were unique to a single type, and 515 peptides, derived from 126 proteins, were shared across cyst types. 32 peptides originating from 12 proteins had differential (adjusted

Indexed as

Mass SpectrometryAdultAgedFemaleHumansMaleMiddle AgedNeoplasm ProteinsPancreatic CystPancreatic NeoplasmsNeoplasm Proteins

Identifiers

PMID30627566
PMCPMC6304507
OpenAlexW2903064452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.